• FLASCO
• March 10, 2015
• Drugs

FDA Approves Palbociclib for Metastatic Breast Cancer

The U. S. Food and Drug Administration granted accelerated approval to palbociclib (IBRANCE®, Pfizer, Inc.) for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast for their metastatic disease. Read more